Role of varicocele sclerotherapy in the management of benign prostatic hyperplasia and its associated lower urinary tract symptoms (pilot study)

Egyptian Journal of Radiology and Nuclear Medicine

Table 2 Demonstrates the statistical analysis of the changes in the degrees of sexual satisfaction, prostatic volumes, post-void residual volumes, maximum urinary flow rates, and PSA levels pre and post sclerotherapy

	Pre	Post	Test value	P value	Sig
	No. = 36	No. = 36	Test value	P value	Sig
Post void residual volume (ml)
Mean ± SD	124.17 ± 12.57	122.48 ± 11.57	− 1.928^•	0.063	NS
Range	100–160	100–150	− 1.928^•	0.063	NS
Prostatic volume (cc)
Mean ± SD	68.97 ± 17.38	63.85 ± 16.63	− 1.948^•	0.060	NS
Range	40–120	30–115	− 1.948^•	0.060	NS
PSA (ng/ml)
Median (IQR)	10 (8.5–11)	9 (8.5–10)	− 1.765^‡	0.077	NS
Range	7–12	7–12	− 1.765^‡	0.077	NS
Q-max
Median (IQR)	10 (9–10)	10 (8–11)	− 1.607^‡	0.108	NS
Range	7–15	7–15	− 1.607^‡	0.108	NS
Sexual satisfaction
Dissatisfied	17 (47.3%)	13 (36.1%)	4.337*	0.114	NS
Neutral	16 (44.4%)	11 (30.6%)
Satisfied	3 (8.3%)	9 (25.0%)
NA	0 (0.0%)	3 (8.3%)

P value > 0.05: non significant (NS); P value < 0.05: significant (S); P value < 0.01: highly significant (HS)
^•Paired t-test
^‡Wilcoxon Rank test (P value > 0.05: non significant (NS); P value < 0.05: significant (S); P value < 0.01: highly significant (HS))